在治疗成人甲状腺功能障碍症后的癌症死亡率. 合作型甲状腺毒素治疗后续研究小组
1Radiation Epidemiology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
JAMA
|August 1, 1998
概括
对甲状腺功能障碍的放射性 (131I) 治疗显示,整体癌症死亡率没有显著增加. 虽然存在小额甲状腺癌风险,但131I仍然是一个安全的治疗选择.
科学领域:
- 内分泌学 在内分泌学.
- 在瘤学瘤学.
- 核医学是一种核医学.
背景情况:
- 高剂量的放射性 (131I) 是美国甲状腺功能增大症的主要治疗方法.
- 有限的证据将131I与癌症联系起来,由于其广泛使用,需要进一步调查.
研究的目的:
- 评估甲状腺功能过高患者的癌症死亡率,特别是检查131I治疗后的结果.
- 评估与不同甲状腺功能障碍治疗方式相关的长期癌症风险.
主要方法:
- 这是一项追溯性队列研究,涉及35593名甲状腺功能障碍患者,他们在1946年至1964年期间接受治疗.
- 数据来自美国和英格兰的26家诊所.
- 标准化癌症死亡率 (SMR) 计算为接受131I,抗甲状腺药物或手术的患者.
主要成果:
- 总体癌症死亡率与一般人群相比 (SMR 1.02对131I).
- 在131I治疗后观察到甲状腺癌死亡率的风险增加 (SMR 3.94),尽管绝对过量很小.
- 在接受抗甲状腺药物治疗的患者 (SMR 1.31) 和有毒结节的患者 (SMR 1.16) 中,癌症死亡率较高.
结论:
- 甲状腺功能障碍本身和131I治疗并没有显著提高整体癌症死亡风险.
- 在131I之后观察到的甲状腺癌死亡率的增加是最小的,可能与潜在的甲状腺疾病有关.
- 放射性 (131I) 被认为是对甲状腺功能障碍的安全有效治疗方法.
相关概念视频
01:21Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
01:27Hyperthyroidism II: Pathophysiology
Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH receptors...
01:28Graves' Disease I: Introduction
Graves' disease is an autoimmune disorder that causes hyperthyroidism, or overactivity of the thyroid gland. It results from autoantibodies called thyroid-stimulating immunoglobulins (TSIs), which bind to thyroid-stimulating hormone (TSH) receptors, leading to overstimulation of hormone production and a hypermetabolic state.EtiologyAlthough considered idiopathic, Graves’ disease has well-established contributing factors. There is a strong genetic component, with increased prevalence in...